CTLA4 and chordoma: In contrast to the above encouraging results, a Phase II clinical study on PD-L1 monoclonal antibody combined with CTLA-4 monoclonal antibody for advanced or metastatic bone tumors showed that among the 5 chordoma patients included in the study, only 1 patient had obvious tumor shrinkage and achieved CR after receiving a full course of twelve cycles (53).